Quarterly ResultJun 3, 2026, 07:31 AM
Avalyn Completes $345M IPO; Q1 Net Loss $26.9M; Pipeline Progress
AI Summary
Avalyn Pharma announced its Q1 2026 financial results and recent business highlights, including the completion of an upsized initial public offering (IPO) that raised $345.0 million in gross proceeds. This capital, combined with existing cash, is projected to fund operations into 2029. The company reported a net loss of $26.9 million for the quarter, an increase from the prior year, driven by increased R&D and G&A expenses. Avalyn also provided updates on its clinical pipeline, with AP01's MIST Phase 2b trial on track for mid-2026 enrollment completion and AP02's AURA Phase 2 trial underway, with topline data for both anticipated in late 2027.
Key Highlights
- Upsized IPO raised $345.0 million in gross proceeds in May 2026.
- Cash, cash equivalents, and marketable securities were $123.1 million as of March 31, 2026.
- Total funding, including IPO proceeds, projected to fund operations into 2029.
- Net loss for Q1 2026 was $26.9 million, up from $17.5 million in Q1 2025.
- R&D expenses increased to $22.9 million in Q1 2026 from $15.3 million in Q1 2025.
- G&A expenses rose to $5.0 million in Q1 2026 from $3.4 million in Q1 2025.
- MIST Phase 2b trial for AP01 on track to complete enrollment mid-2026.
- AURA Phase 2 trial for AP02 enrollment underway, topline data late 2027.
Price Impact
More from AVLN